The PE Ratio as of December 2025 (TTM) for Liminatus Pharma, Inc. Class A Common Stock (LIMN) is -5.96

According to Liminatus Pharma, Inc. Class A Common Stock’s latest financial reports and current stock price. The company's current PE Ratio is -5.96. This represents a change of -99.98% compared to the average of -33094.50 of the last 4 quarters.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Historical PE Ratio (quarterly & annually)

How has LIMN PE Ratio performed in the past?

The mean historical PE Ratio of Liminatus Pharma, Inc. Class A Common Stock over the last ten years is -16.12. The current -5.96 PE Ratio has changed 3.60% with respect to the historical average. Over the past ten years (40 quarters), LIMN's PE Ratio was at its highest in in the June 2025 quarter at 573.34. The PE Ratio was at its lowest in in the March 2025 quarter at -132934.95.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Liminatus Pharma, Inc. Class A Common Stock PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Average PE Ratio

How has LIMN PE Ratio performed in the past?

The current PE Ratio of Liminatus Pharma, Inc. Class A Common Stock (LIMN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Liminatus Pharma, Inc. Class A Common Stock (LIMN) PE Ratio vs. Peers

How is LIMN’s PE Ratio compared to its peers?

Liminatus Pharma, Inc. Class A Common Stock’s PE Ratio is less than Alterity Therapeutics Limited (-4.93), less than NanoViricides, Inc. (-0.00), less than Generation Bio Co. (-0.48), less than Mural Oncology plc (-0.24), greater than Evaxion Biotech A/S (-9.76), less than BioXcel Therapeutics, Inc. (-0.32), less than Jasper Therapeutics, Inc. (-0.44), less than Dyadic International, Inc. (-5.40), less than SAB Biotherapeutics, Inc. (2.16), less than MAIA Biotechnology, Inc. (-2.25),

Build a custom stock screener for Liminatus Pharma, Inc. Class A Common Stock (LIMN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Liminatus Pharma, Inc. Class A Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Liminatus Pharma, Inc. Class A Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.